Italian medtech startup MMI received a €17 million co‑investment from Angelini Ventures and the European Investment Bank, strengthening its Symani robotic micro‑surgery platform and marking the first deal under the BEI‑Angelini Ventures health‑tech partnership.
Polish startup GPN-Star has unveiled a powerful AI‑driven platform that works like a “genetic ChatGPT” to pinpoint DNA variants influencing organism traits and disease susceptibility. Independent testing by UC Berkeley showed the tool beats existing genomic approaches and can be trained with far lower resource demands than the largest genome‑focused models.
Eterna Regeneratives, a spin‑out from King’s College London, is developing a keratin‑based biomaterial to repair tooth enamel and bone, and raised a $4 million seed round led by Hoxton Ventures and The Venture Collective.
Swedish startup Halmos Labs aims to speed up the development of new medicines using artificial intelligence and has secured a spot in the renowned US accelerator Y Combinator.
A MEDIjobs press release reports the results of a survey of Romanian medical staff conducted in August‑September 2026. The study finds that 55% would choose a public‑sector job if pay were equal, 45% view public salaries as more attractive, and private offers vary widely by specialty and experience. The platform highlights the importance of salary, bonuses, working conditions and equipment in job decisions.
Quantum Innovations, a Polish medtech startup, received a grant from the Polish Agency for Enterprise Development under the SMART Path to create a tiny system that continuously measures lactate levels in interstitial fluid in real time.
Cofertility, a new fertility startup, will freeze women’s eggs for free on the condition that the women keep half of the retrieved eggs. The company is led by former Uber executive Lauren Makler.
Swiss preventive health startup Aeon raised a seed extension, bringing its total seed funding to over €12 million, and used the round to acquire German blood‑diagnostics platform Aware Health, expanding its AI‑driven whole‑body imaging and biomarker offering across Europe.
Snelix, an Italian biotech startup that turns snail mucus into bio‑active peptides for cosmeceutical and nutraceutical applications, raised more than €1 million through three public grant schemes, minimizing equity dilution while advancing its product pipeline.
Aiom is urging US biotech company Revolution Medicines to launch a compassionate‑use program for daraxonrasib, a targeted therapy that has doubled survival in a pancreatic cancer trial. While the drug received FDA approval in the United States, no similar early‑access program exists in Europe, and Revolution Medicines has not submitted a registration dossier to the European Medicines Agency. Aiom and Italian oncologists argue the drug should be provided free of charge to Italian patients pending approval, citing ethical concerns over high import costs.